Rh-positive and Rh-negative blood
Most people in many populations are Rh-positive, although the proportions differ across ancestry groups. Rh-negative blood is less common in some populations and more common in others.
These differences matter for blood donation and transfusion services. Hospitals need to know a patient's blood group to select compatible blood products and reduce the risk of immune reactions.
During pregnancy, Rh status can also be relevant. If an Rh-negative pregnant person carries an Rh-positive fetus, fetal red blood cells entering the pregnant person's circulation can sometimes trigger the production of antibodies against the D antigen. Those antibodies may affect a future Rh-positive pregnancy. Appropriate prenatal testing and preventive treatment have greatly reduced the risk of serious complications.
These are well-established clinical reasons to know Rh status. They are separate from claims about lifespan.
Does being Rh-positive mean better health?
There is no strong evidence that being Rh-positive or Rh-negative, by itself, determines a person's overall life expectancy. Research may investigate associations between blood-group characteristics and particular conditions, but results must be interpreted carefully.
A person's Rh status does not tell a clinician whether that person has high blood pressure, diabetes, a harmful cholesterol level, or an elevated risk of a particular cancer. Those conditions require their own assessment.
Nor should people assume that Rh-negative blood is rare enough to make someone biologically unusual in a way that predicts exceptional longevity. Rarity is not the same as a health advantage.
Why blood-group information is still valuable
Blood-group classification remains essential in medicine because compatibility matters. A transfusion requires careful matching, and additional blood-group systems beyond ABO and Rh may also be relevant in particular circumstances.
Blood groups are inherited, so they can also be useful in genetic and population research. Scientists may study them alongside other inherited characteristics to explore disease patterns. But an association found in a population does not necessarily translate into a useful prediction for an individual.
Knowing your blood type is useful information, particularly for medical care and blood donation. It is not a substitute for routine health assessments, and it cannot tell you how long you will live.
Chapter 3: Why Scientists Study Blood Type and Longevity
The question of whether blood type influences longevity is not entirely unreasonable. Blood groups are inherited biological characteristics, and researchers have found that the ABO system is associated with certain physiological differences. Those differences may influence some disease risks, which could potentially affect health over a lifetime.
The challenge is determining how large those effects are and whether they meaningfully influence the probability of reaching an advanced age.
What does longevity research actually measure?
Researchers can approach longevity in several ways. Some studies examine life expectancy in large populations. Others compare people who have reached very old ages with people from younger age groups. Some focus on centenarians—people who live to 100 or beyond—while others investigate survival over a defined period.
These approaches do not necessarily answer the same question.
A study that compares blood groups among people already aged 100 may reveal whether certain groups are more or less common in that sample. However, it cannot automatically establish that the blood group caused their longevity. The result may be influenced by ancestry, geography, historical circumstances, sample size, and other factors.
A stronger investigation would need reliable information about blood type, age, health history, and survival over time. Researchers would also need to account for differences in lifestyle, access to healthcare, family history, and other factors that can affect the probability of reaching 100.
Why a group of centenarians is not enough
Imagine that a study finds a relatively high proportion of people with type O among a group of centenarians. It might be tempting to conclude that type O helps people live longer.
But several questions would need to be answered first.
Was type O already common in the population from which those centenarians came? Were the participants from a particular region or ancestry group? Did the study include enough people to distinguish a real association from random variation? Were blood groups recorded accurately? Did researchers compare the results with an appropriate reference population?
Without this information, the observation could be misleading.
For example, a blood group may be common among centenarians simply because it is common in the surrounding population. A different blood group may appear unusually frequent because the sample happens to contain people from a region where that group is prevalent.
This is why population comparisons require careful statistical analysis.
Association is not causation
An association means that two things occur together more often than expected under a particular analysis. Causation means that one factor contributes directly to producing an outcome.
The distinction is central to medical research.
People with a particular blood group may have a different average risk of a certain disease. Yet that does not necessarily mean the blood group alone causes the disease, and it certainly does not prove that it determines lifespan.
Other variables may influence the observed relationship. Some may be known and measurable; others may be difficult to account for completely.
Even when a biological mechanism is plausible, researchers still need evidence that the mechanism produces a meaningful difference in real-world outcomes.
What would strong evidence look like?
To establish a reliable relationship between blood type and reaching 100, researchers would ideally examine large, diverse populations and follow participants over time. They would need to account for age, sex, ancestry, health conditions, lifestyle, and relevant social factors.
The results would also need to be replicated in independent populations. If a finding appeared in one country but disappeared in several others, scientists would need to investigate why.
Finally, researchers would need to assess whether blood type improves predictions beyond information already available from conventional health indicators. A factor can have a statistically detectable association while contributing little practical value to an individual's risk assessment.
At present, the available evidence does not justify declaring A, B, AB, or O the blood type most likely to reach 100.
The question remains scientifically interesting, but the honest answer is that a simple ranking of blood groups by lifespan is not supported by sufficiently strong evidence.
Chapter 4: Blood Type O and the Question of Cardiovascular Risk
Blood type O often appears in discussions of longevity because research has identified differences between people with type O blood and those with non-O blood groups in certain aspects of blood clotting.
These findings are real areas of medical research, but they need to be described accurately. A lower average risk of one condition does not automatically mean a longer lifespan overall.
The role of von Willebrand factor
Von Willebrand factor is a protein that helps platelets attach to damaged blood vessels and supports the blood-clotting process. It also carries and stabilizes another clotting protein, factor VIII.
The ABO blood-group system influences average levels of von Willebrand factor in the blood. On average, people with non-O blood groups tend to have higher levels than people with type O, although individual levels vary considerably.
This difference provides a plausible biological explanation for some observed associations between blood groups and clotting-related conditions.